Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Australia approves rapid syphilis test for nationwide use to combat rising cases and improve maternal and infant health.
Australia has approved bioLytical’s iStatis Syphilis Antibody Test for nationwide use, adding it to the Register of Therapeutic Goods (ARTG: 515126).
The rapid, point-of-care test detects syphilis antibodies from a fingerstick blood sample, delivering results in under 15 minutes.
It is portable, stable at room temperature, and requires no cold storage or complex equipment, making it suitable for remote and underserved clinics.
The test supports early diagnosis amid rising syphilis rates—5,866 cases reported in 2024, double the 2014 level—and a growing number of congenital syphilis cases and infant deaths.
Its inclusion strengthens public health efforts to curb transmission and improve maternal and infant outcomes.
Healthcare providers can obtain the test through authorized distributors or directly from bioLytical.
Australia aprueba la prueba rápida de sífilis para su uso en todo el país para combatir el aumento de casos y mejorar la salud materna e infantil.